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Background: the most appropriate timing for implantable cardioverter-defibrillator (ICD) implantation in Idiopathic Dilated Cardiomyopathy 
(DCM) is not well defined: some patients dramatically improve after medical treatment optimization, but an excessive delay for the sudden death 
stratification can be hazardous. Our aim was to identify patients with DCM unlikely to improve despite optimization of medical treatment, including 
betablockers, and therefore potentially candidates for early ICD implantation .
methods: among 720 patients with DCM registered in the Heart Muscle Disease Registry of Trieste (Italy) from January 1st 1988 to May 31st 
2011, 188 with baseline left ventricular ejection fraction (LVEF) ≤0.35 and NYHA classes II-III (“SCDHeFT criteria”) were evaluated both before 
starting betablockers and after 6±3 months. A prognostic model for the identification, at diagnosis, of patients with DCM more likely to maintain ICD 
indication, or die, after 6±3 months was assessed. Thereafter, the model was prospectively validated on an external similar group.
results: of 188 patients with baseline LVEF≤0.35 and NYHA classes II-III, 70 (37%) maintained “SCDHeFT criteria” or were died (n=13; 7%) after 
6±3 months. At multivariate analysis, the presence at baseline of lower systolic blood pressure (OR for interquartile increase=0.52; 95% C.I. 0.32-
0.83), LV end-diastolic volume >110 ml/m2 (OR=2.63; 95% C.I. 1.28-5.40), larger left atrial diameter (OR for interquartile increase=1.72; 95% 
C.I. 1.07-2.78), significant mitral regurgitation (OR=2.18; 95% C.I. 1.05-4.5), left bundle branch block (OR=2.17; C.I. 1.06-4.43) predicted the 
persistence of “SCDHeFT criteria” or death at second evaluation. The individual probability of maintaining ICD indication despite medical therapy 
was calculated and the model was validated internally and prospectively on a separate group of 20 DCM patients (AUC: 0.85, 95% C.I. 0.67-1.00).
conclusions: in DCM many patients improve 6±3 months after diagnosis, but others still have ICD indication or die despite optimal treatment. 
Applying simple clinical-instrumental parameters it is possible to identify potential candidates for early ICD implantation.
